Idiopathic myelofibrosis: A clinical review

International Journal of Hematology

Volumn 68, Issue 4, 1998, Pages 355-362

  Manoharan, Arumugam ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Diagnosis; Myelofibrosis; Pathophysiology; Prognosis; Treatment

Indexed keywords

ALPHA INTERFERON; ANABOLIC AGENT; BUSULFAN; CHLORAMBUCIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; RECOMBINANT ERYTHROPOIETIN; TIOGUANINE;

ANEMIA; CLINICAL FEATURE; DISEASE COURSE; HUMAN; MYELOFIBROSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLENECTOMY; SPLENOMEGALY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031773101     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(98)00052-8     Document Type: Review

References (66)

1. Jacobson R.S., Salo A., Fialkow P.S. Agnogenic myeloid metaplasia: a clonal proliferation of hemopoietic stem cells with secondary myelofibrosis. Blood. 51:1978;189-194.
2. Sato Y., Suda T., Suda J.et al. Multilineage expression of haemopoietic precursors with an abnormal clone in idiopathic myelofibrosis. Br J Haematol. 64:1986;657-667.
3. Kreipe H., Jaquet K., Felgner J., Radzun H.J., Parwaresch M.R. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood. 78:1991;1814-1991.
4. Castro-Malaspina H. Pathogenesis of myelofibrosis. Prog Clin Biol Res. 154:1984;427-454.
5. Kimura A., Katoh D., Hyodo I.T., Kuramoto A. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow of fibroblasts. Br J Haematol. 72:1989;486-491.
6. Terui T., Niitsu Y., Mahara K.et al. The production of transforming growth factor beta in acute megakaryoblastic leukaemia and its possible implications in myelofibrosis. Blood. 75:1990;1540-1548.
7. Thiele J., Rompcik V., Wagner S., Fischer R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera. Br J Haematol. 80:1992;227-234.
8. Reilly J.T., Barnett D., Dolan G., Forrest P., Eastham J., Smith A. Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol. 83:1993;58-62.
9. Martyre M.C., Romquin N., Le Bousse-Kerdices M.C.et al. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 88:1994;9-16.
10. Dalley A., Smith J.M., Reily J.T., MacNeil S. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol. 93:1996;856-862.
11. Yanagida M., Ide Y., Imai A.et al. The role of transforming growth factor-β in PEG-r Hu MGDF-induced reversible myelofibrosis in rats. Br J Haematol. 99:1997;739-745.
12. Hiti-Harper J., Wohl H., Harper E. Platelet factor 4: an inhibitor of collagenase. Science. 199:1978;991-992.
13. Reilly J.T., Brindley L., Kay M.et al. Bone marrow and serum connective tissue polypeptides in idiopathic myelofibrosis. Clin Lab Haematol. 17:1995;35-39.
14. Hasselbalch H., Junker P., Horslev-Paterson K., Lisse I., Bentsen K.D. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions. Am J Hematol. 33:1990;18-26.
15. McCarthy D.M. Fibrosis of the bone marrow: content and causes. Br J Haematol. 59:1985;1-7.
16. Ramakrishna R., Kyle P.W., Day P.J., Manoharan A. Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Pathology. 27:1995;255-259.
17. Pitcock J.A., Reinhard E.H., Justus B.W., Mendelsohn R.S. A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med. 57:1962;73-84.
18. Manoharan A., Chen C.F., Wilson L.S., Griffiths K.A., Robinson D.E. Ultrasonic characterization of splenic tissue in myelofibrosis: further evidence for reversal of fibrosis with chemotherapy. Eur J Haematol. 40:1988;149-154.
19. Manoharan A., Gill R.W., Griffiths K.A. Splenic blood flow measurements by Doppler ultrasound: a preliminary report. Cardiovasc Res. 21:1987;779-782.
20. Tsao M.S. Hepatic sinusoidal fibrosis in agnogenic myeloid metaplasia. Am J Clin Pathol. 91:1989;302-305.
21. Bouroncle B.A., Doan C.A.F. Myelofibrosis: Clinical, hematologic and pathologic study of 110 patients. Am J Med Sci. 243:1962;697-715.
22. Varki A., Lottenberg R., Griffith R., Reinhard R. The syndrome of idiopathic myelofibrosis: a clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine. 62:1983;353-371.
23. Manoharan A., Pitney W.R. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol. 33:1984;453-459.
24. Towell B.L., Levine S.P. Massive Hepatomegaly following splenectomy for myeloid metaplasia: case report and review of literature. Am J Med. 82:1987;371-375.
25. Shaver R.W., Close F.C. Extramedullary hemopoiesis in myeloid metaplasia. Am J Roentgenol. 137:1981;874-876.
26. Loewy G., Mathew A., Distenfeld A. Skin manifestation of agnogenic myeloid metaplasia. Am J Hematol. 45:1994;167-170.
27. Wajima T. Agnogenic myeloid metaplasia and malignant pleural effusion caused by extramedullary hematopoiesis. Chest. 106:1994;322-323.
28. Barosi G., Cazzoli M., Frassoni F., Orlandi E., Stefanelli M. Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics. Br J Haematol. 48:1981;263-272.
29. Njoku O.S., Lewis S.M., Catovsky D., Gordon-Smith E.C. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol. 54:1983;79-89.
30. MN Silverstein. Treatment of myelofibrosis. In: SM Lewis, editor. Myelofibrosis: Pathophysiology and Clinical Management. New York: Marcel Dekker, 1985:195-202.
31. Bird G.W., Wingham J., Richardson S.G. Myelofibrosis, auto-immune haemolytic anaemia and polyagglutinability. Haematologia. 18:1985;99-103.
32. Di Bella N.J., Silverstein M.N. Effect of splenectomy on teardrop-shaped erythrocytes in agnogenic myeloid metaplasia. Arch Intern Med. 137:1977;380-381.
33. Manoharan A., Hargrave M., Gordon S. Effect of chemotherapy on teardrop poikilocytes and other peripheral blood findings in myelofibrosis. Pathology. 20:1988;7-9.
34. Manoharan A., Smart R.C., Pitney W.R. Prognostic factors in myelofibrosis. Pathology. 14:1982;455-461.
35. Wolf B.C., Neiman R.S. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood. 65:1985;803-809.
36. Thiele J., Hoeppner B., Zankovich R., Fischer R. Histomorphometry of bone marrow biopsies in primary osteo-myelofibrosis-sclerosis (agnogenic myeloid metaplasia). Virchows Arch (A). 415:1989;191-202.
37. Metcalf D., Gearing D.P. A myelosclerotic syndrome in mice engrafted with cells producing high levels of leukemia-inhibitory factor (LIF). Leukemia. 3:1989;847-853.
38. Jay P.R., Centrella M., Lorenzo J., Bruce A.G., Horowitz M.C. Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption. Endocrinology. 137:1996;1151-1158.
39. Ward H.P., Block M.H. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine. 50:1971;357-420.
40. Barosi G., Berzuini C., Liberato L.N., Costa A., Polina G., Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 70:1988;397-401.
41. Viscani G., Finelli C., Castelli U.et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 75:1990;4-9.
42. Rupoli S., Da Lio L., Sisti S.et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol. 68:1994;205-212.
43. Thiele J., Kvasnicka H.M., Werden C., Zancovich R., Diehl V., Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythaemia and variables of prognostic impact. Leuk Lymphoma. 22:1996;303-317.
44. Dupriez B., Morel P., Demory J.L.et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 88:1996;1013-1018.
45. Cervantes F., Pereira A., Esteve J.et al. Identification of short-lived and long-lived patients at presentation of idiopathic myelofibrosis. Br J Haematol. 97:1997;635-640.
46. Manoharan A. Myelofibrosis: prognostic factors and treatment. Br J Haematol. 69:1988;295-298.
47. Sivera P., Cesano L., Guerrasio A.et al. Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis. Br J Haematol. 86:1994;397-398.
48. Fruchtman S.M., Scigliano E., Wasserman L.R. Recombinant erythropoietin (rHuEpo) can be an effective agent in transfusion dependent myelofibrosis. Blood. 76:1990;271.
49. Rodriguez J.N., Martino M.L., Muniz R., Prados D. Recombinant human erthropoietin for the treatment of anemia in myelofibrosis with myeloid metaplasia. Am J Hematol. 48:1995;135-136.
50. Rozman C., Giralt M., Feliu E., Rubio D., Cortes M.T. Life expectancy of patients with chronic non-leukemic myeloproliferative disorders. Cancer. 67:1991;2658-2663.
51. Lofvenberg E., Wahlin A., Roos G., Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol. 44:1990;33-38.
52. Chang J.C., Gross H.M. Case report: remission of chronic idiopathic myelofibrosis to busulphan treatment. Am J Med Sci. 295:1988;472-476.
53. Manoharan A. Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol. 71:1991;252-254.
54. Tefferi A., Silverstein M.N., Noel P. Agnogenic myeloid metaplasia. Semin Oncol. 22:1995;327-333.
55. Oishi N., Swisher S.N., Troup S.B. Busulphan therapy in myeloid metaplasia. Blood. 15:1960;863-872.
56. Pegrum G.D., Foadi M., Boots M., Clare M. How should we manage myelofibrosis? J Roy Coll Phys. 15:1981;17-18.
57. Nand S., Stock W., Godwin J., Fisher S.G. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol. 52:1996;42-46.
58. Przepiorka D., Giralt S., Khouri I., Champlin R., Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol. 57:1998;24-28.
59. Silver R.T. Interferon in the treatment of myeloproliferative diseases. Semin Hematol. 27(Suppl 4):1990;6-14.
60. Barosi G., Liberato L.N., Costa A.et al. Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur J Haematol. 45(suppl 52):1990;12-14.
61. Dalla K.P., Zeigler Z.R., Shadduck R.K. Alpha-interferon in myelofibrosis: a case report. Br J Haematol. 86:1994;654-656.
62. Barosi G., Ambrosetti A., Buratti A.et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia. 7:1993;200-206.
63. Benbassat J., Penchas S. Early splenectomy and survival in agnogenic myeloid metaplasia. Acta Haematol. 65:1981;189-192.
64. Petroianu A. Subtotal splenectomy for treatment of patients with myelofibrosis and myeloid metaplasia. Int. Surg. 81:1996;177-179.
65. Wagner H., McKeough P.G., Desforges J., Madoc-Jones H. Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia: results of daily and intermittent fractionation with and without concommitant hydroxyurea. Cancer. 58:1986;1204-1207.
66. Price F., Bell H. Spinal Cord compression due to extramedullary hematopoiesis. Successful treatment in a patient with long-standing myelofibrosis. J Am Med Assoc. 253:1985;2876-2877.